Beyond Obesity: Eli Lilly's Genetic Medicine Bet On Verve Therapeutics
1. Eli Lilly acquires Verve Therapeutics for $1.3 billion, boosting its cardiovascular portfolio. 2. The deal represents a 113% premium, indicating strong strategic value. 3. Lilly's valuation remains attractive even after the acquisition premium. 4. Market volatility and reliance on obesity drugs present risks for Lilly. 5. The acquisition highlights Lilly's strategy of diversification into genetic medicine.